ArticleJournal of molecular neuroscience : MN2001
Dysferlin protein analysis in limb-girdle muscular dystrophies.
Article in Journal of molecular neuroscience : MN, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00138931 (Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.
Who cites it
19 citing papers in PubMed, 85 citations in OpenAlex.
- Impaired myogenesis in limb girdle muscular dystrophy type 2B.Scientific reports · 2025Article
- Recurrent, non-traumatic, non-exertional rhabdomyolysis after immunologic stimuli in a healthy adolescent female: a case report.BMC pediatrics · 2022Article
- A Journey with LGMD: From Protein Abnormalities to Patient Impact.The protein journal · 2021Review
- Diagnostic muscle biopsies in the era of genetics: the added value of myopathology in a selection of limb-girdle muscular dystrophy patients.Acta neurologica Belgica · 2021Article
- Article
- Faster regeneration associated to high expression of Fam65b and Hdac6 in dysferlin-deficient mouse.Journal of molecular histology · 2019Article
- High-throughput Measurement of Plasma Membrane Resealing Efficiency in Mammalian Cells.Journal of visualized experiments : JoVE · 2019Article
- Myoferlin, a Membrane Protein with Emerging Oncogenic Roles.BioMed research international · 2019Review
- Atypical Miyoshi distal myopathy: A case report.Experimental and therapeutic medicine · 2016Article
- Screening two mutations in the dysferlin gene by exon capture and sequence analysis: A case report.Experimental and therapeutic medicine · 2016Article
- Dysferlinopathy Fibroblasts Are Defective in Plasma Membrane Repair.PLoS currents · 2015Article
- Genetic silencing of Nrf2 enhances X-ROS in dysferlin-deficient muscle.Frontiers in physiology · 2014Article
- Differential expression of genes involved in the degeneration and regeneration pathways in mouse models for muscular dystrophies.Neuromolecular medicine · 2012Article
- Distinct effects of contraction-induced injury in vivo on four different murine models of dysferlinopathy.Journal of biomedicine & biotechnology · 2012Article
- Dysferlinopathy course and sportive activity: clues for possible treatment.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2011Article
- From proteins to genes: immunoanalysis in the diagnosis of muscular dystrophies.Skeletal muscle · 2011Article
- Diaphragm displays early and progressive functional deficits in dysferlin-deficient mice.Muscle & nerve · 2010Article
- Clinical and pathological characteristics of four Korean patients with limb-girdle muscular dystrophy type 2B.Journal of Korean medical science · 2004Article
- Muscle histopathology in today's era of molecular genetics: Role and limitations.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysferlin is the protein product of the DYSF gene mapped at 2p31, which mutations cause limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy. To date, nine autosomal recessive forms (AR-LGMD) have been identified: four genes, which code for the sarcoglycan glycoproteins, are associated with both mild and severe forms, the sarcoglycanopathies (LGMD2C, 2D, 2E and 2F). The other five forms, usually causing a milder phenotype are LGMD2A (calpain 3), LGMD2B (dysferlin), LGMD2G (telethonin), LGMD2H (9q31-11), and LGMD21 (19q13.3). We studied dysferlin expression in a total of 176 patients, from 166 LGMD families: 12 LGMD2B patients, 70 with other known forms of muscular dystrophies (LGMD2A, sarcoglycanopathies, LGMD2G), in an attempt to assess the effect of the primary gene-product deficiency on dysferlin. In addition, 94 still unclassified LGMD families were screened for dysferlin deficiency. In eight LGMD2B patients from five families, no dysferlin was observed in muscle biopsies, both through immunofluorescence (IF) and Western blot methodologies, while in two families, a very faint band was detected. Both patterns, negative or very faint bands, were concordant in patients belonging to the same families, suggesting that dysferlin deficiency is specific to LGMD2B. Myoferlin, the newly identified homologue of dysferlin was studied for the first time in LGMD2B patients. Since no difference was observed between patients mildly and severely affected, this protein do not seem to modify the phenotype in the present dysferlin-deficient patients. Dystrophin, sarcoglycans, and telethonin were normal in all LGMD2B patients, while patients with sarcoglycanopathies (2C, 2D, and 2E), LGMD2A, LGMD2G, and DMD showed the presence of a normal dysferlin band by Western blot and a positive pattern on IF. These data suggest that there is no interaction between dysferlin and these proteins. However, calpain analysis showed a weaker band in four patients from two families with intra-familial concordance. Therefore, this secondary deficiency of calpain in LGMD2B families, may indicate an interaction between dysferlin and calpain in muscle. Dysferlin was also present in cultured myotubes, in chorionic villus, and in the skin. Dysferlin deficiency was found in 24 out of a total of 166 Brazilian AR-LGMD families screened for muscle proteins (approximately 14%), thus representing the second most frequent known LGMD form, after calpainopathy, in our population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.